Body-Mass-Index (BMI) und Lebensqualität (QoL) bei Krebspatienten (BMI-QoL)
BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated.
High BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 or the EQ-5D-5L questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
Health-related quality of life (HRQoL) might have a varied association with body weight in patients with solid cancer[1].
On one hand, low body weight may reflect cancer-related anorexia and weight loss and cachectic syndrome, which are associated with impaired performance status, deteriorated general conditions, and advanced cancer[2]. In such patients, the probability of recording a low Body Mass Index (BMI) and, concomitantly, an inferior health-related quality of life (HRQoL, as a patient reported outcome, PRO) is high.
On the other hand, some of the hormonal mediators found at increased concentration in obese patients, such as insulin-like growth factor (IGF), have been demonstrated to be involved in biological pathways that favor improved HRQoL[3].
An additional apparent contradiction is that obesity and high BMI may represent in some cancer settings an adverse feature. In particular, obesity is associated with an increased risk of developing certain tumor types and, in some cancer patients with radically resected primary tumors, of cancer relapse[4]. Moreover high BMI is often associated with an increased burden of comorbidity (e.g. cardiovascular and metabolic diseases)[5] and reduced physical activity. All these factors may reduce HRQoL.
Studies investigating specific associations between BMI and HRQoL in specific cancer settings are therefore warranted.
The present prospective observational cohort study aims to investigate the relationship between BMI and PRO-HRQoL as measured by the EORTC-QLQ-C30 or the EQ-5D-5L questionnaire [6] in different primary tumors (breast, lung, colorectal and others) and in different cancer stages (localized vs metastatic). Patients will also be stratified according to the presence of cardiovascular and metabolic comorbidities, the Karnofsky Performance status, and the oncological treatment received (systemic treatment vs radically resected patients on follow-up). If available, retrospective data will be used to train possible predictive models.
STUDY PROCEDURES Study participation will be offered to all consecutive patients with a histologically confirmed diagnosis of solid tumor referred to the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/). Upon acceptance, patients will sign an informed consent forms and be asked to fill out the EORTC QLQ C30 or EQ-5D-5L questionnaire.
All common anthropometric, demographic, clinical, and biochemical variables will be recorded at the time of first referral (within three months).
Re-assessable variables, including re-administration of the EORTC QLQ-C30/EQ-5D-5L questionnaire, will be recorded every 4-6 months thereafter. All data will be stored in a prospectively maintained database.
Among recorded data will be: age, sex, weight, height, occupation, marital status, primary tumor site, tumor stage, possible metastatic sites, past and current type of oncological treatment, concomitant medications, Karnofsky Performance Status, vital signs, and routine and clinically relevant blood tests.
Patients will be oncologically managed according to standard practice. If indicated, patients will also be asked to provide consent for peripheral blood sampling for immune response evaluation. Association between BMI and PROs will be assessed using regression analyses across the different clinical settings identified.
STATISTICAL CONSIDERATIONS The design of the study hypothesizes that in metastatic patients an improved HR-QoL is associated with high BMI (non-cachectic patients) An 'exact single-stage design' will be followed [7]. According to historical data (endometrial cancer), 50% of patients with BMI < 30 have a high global health status score (GHS) of the EORTC QLQ C30 (i.e. a GHS score ≥ 80%, which would correspond to a EQ-5D-5L index ≥ 0.85) [8].
The hypothesis to be tested will be H0, P < P0 vs H1, P > P1, where P is the percentage of patients with GHS ≥ 80%. A one-tail alpha error of 0.05 and false-negative (beta) rate of 0.2 will be considered. P0 will be set at 50% and P1 at 65%, looking for a 15% increase in the percentage of high GHS scores among patients with BMI >30. The H0 hypothesis will be rejected and H1 accepted with a statistical power of 80% if at least 42 patients out of 69 with BMI > 30 report a GHS score ≥ 80.
Since BMI > 30 is observed in about 10% of all metastatic patients, a total of 690 metastatic patients will be required. Since metastatic patients represent about half of all cancer patients referred to Medical Oncology Units, a final sample size of 1380 cancer patients (all stages) will be set as the target number. Secondary analyses will evaluate the extent to which clinical and biochemical characteristics documented during the observation period moderate the association between BMI and HRQoL. Additionally, these analyses will quantify the relative contributions of both BMI and HRQoL to anticancer treatment outcomes and overall survival.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Vincenzo Formica, MD, PhD
- Telefonnummer: +390620908190
- E-Mail: v.formica1@gmail.com
Studieren Sie die Kontaktsicherung
- Name: Cristiano Serci
- Telefonnummer: +390620903247
- E-Mail: cserci81@gmail.com
Studienorte
-
-
-
Rome, Italien, 00133
- Rekrutierung
- Tor Vergata University Hospital
-
Kontakt:
- Cristiano Serci
- Telefonnummer: +390620908190
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).
Beschreibung
Inclusion Criteria:
- Histologically confirmed diagnosis of solid tumor
- Age >18 years
- Signed informed consent
- Life expectancy > 12 weeks
Exclusion Criteria:
- Inability to fill out the questionnaires.
- Absence of a certain diagnosis of solid tumor (e.g. subjects on screening programs)
- Diagnosis of second malignancies that might bias results interpretation
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
patients with solid tumor
All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/). |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
relationship between BMI and health-related quality-of-life scores according to tumor stage
Zeitfenster: Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient
|
To assess the relationship between BMI and health-related quality-of-life scores in localized vs metastatic cancer patients |
Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
relationship between BMI and health-related quality-of-life scores according to different clinical settings other than stage
Zeitfenster: Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient
|
- To assess the relationship between BMI and health-related quality-of-life scores according to:
|
Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Studienstuhl: Mario Roselli, Tor Vergata University Hospital
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
- A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001 Mar 30;20(6):859-66. doi: 10.1002/sim.721.
- Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013 Apr 20;31(12):1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25.
- Lin LL, Brown JC, Segal S, Schmitz KH. Quality of life, body mass index, and physical activity among uterine cancer patients. Int J Gynecol Cancer. 2014 Jul;24(6):1027-32. doi: 10.1097/IGC.0000000000000166.
- Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1402-10. doi: 10.1158/1055-9965.EPI-04-0862.
- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16;371(9612):569-78. doi: 10.1016/S0140-6736(08)60269-X.
- Twig G, Yaniv G, Levine H, Leiba A, Goldberger N, Derazne E, Ben-Ami Shor D, Tzur D, Afek A, Shamiss A, Haklai Z, Kark JD. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. N Engl J Med. 2016 Jun 23;374(25):2430-40. doi: 10.1056/NEJMoa1503840. Epub 2016 Apr 13.
- Smits A, Lopes A, Das N, Bekkers R, Galaal K. The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter? Gynecol Oncol. 2014 Jan;132(1):137-41. doi: 10.1016/j.ygyno.2013.11.018. Epub 2013 Nov 18.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- R.S. 102.17
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .